ICMJE DISCLOSURE FORM

Date: August 16, 2021

Your Name: Ashley Hall

Manuscript Title: EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
|   |                                                   |     |
|---|--------------------------------------------------|-----|
| 4 | Consulting fees                                  | None |
| 5 | Payment or honoraria for lectures, presentations,| None |
|   | speakers bureaus, manuscript writing or educational events |     |
| 6 | Payment for expert testimony                      | None |
| 7 | Support for attending meetings and/or travel      | None |
| 8 | Patents planned, issued or pending                | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
|11 | Stock or stock options                            | Yes: Hold stocks and shares in GSK |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
|13 | Other financial or non-financial interests        | Employee of GSK |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: August 16, 2021
Your Name: Anya Harry
Manuscript Title: EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 4 | Consulting fees                                                            | None   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                | None   |
| 7 | Support for attending meetings and/or travel                                | None   |
| 8 | Patents planned, issued or pending                                          | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | None   |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11| Stock or stock options                                                      | Yes: Hold stocks and shares in GSK |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| 13| Other financial or non-financial interests                                  | None   |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: ______ August 16, 2021

Your Name: ______________ David Roth

Manuscript Title: ______ EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials ______

Manuscript number (if known): ______________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Yes:
The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. | Time frame: Since the initial planning of the work |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | Time frame: past 36 months |
| 3 | Royalties or licenses | None | |


|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 4 | Consulting fees                                                             | None   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                | None   |
| 7 | Support for attending meetings and/or travel                                 | None   |
| 8 | Patents planned, issued or pending                                           | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | None   |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11| Stock or stock options                                                       | Yes: Hold stocks and shares in GSK |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| 13| Other financial or non-financial interests                                   | Employee of GSK |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date:______August 16, 2021
Your Name:____________ Jonca Bull
Manuscript Title:_______EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials ________
Manuscript number (if known):____________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.). No time limit for this item. | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| **3** | Royalties or licenses | None |
|   | Consulting fees | Yes: GSK |
|---|----------------|---------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Yes: Carefirst Blue Cross Blue Shield Board Member (stipend) Member of Advisory Board Children’s National Medical Center on Research, Education and Innovation (unpaid) |
| 11 | Stock or stock options | Yes: PPD stock options |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: August 16, 2021
Your Name: James G Groark
Manuscript Title: EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **1** | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| **Time frame: Since the initial planning of the work** | | |
| **2** | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| **Time frame: past 36 months** | | |
| **3** | Royalties or licenses | None |


|   |                                                        |       |
|---|--------------------------------------------------------|-------|
| 4 | Consulting fees                                       | None  |
| 5 | Payment or honoraria for lectures, presentations,     | None  |
|   | speakers bureaus, manuscript writing or educational    |       |
|   | events                                                 |       |
| 6 | Payment for expert testimony                           | None  |
| 7 | Support for attending meetings and/or travel           | None  |
| 8 | Patents planned, issued or pending                     | None  |
| 9 | Participation on a Data Safety Monitoring Board or     | None  |
|   | Advisory Board                                         |       |
| 10| Leadership or fiduciary role in other board, society, | None  |
|   | committee or advocacy group, paid or unpaid            |       |
| 11| Stock or stock options                                 | Yes:  |
|   | Hold stocks and shares in                              | GSK   |
| 12| Receipt of equipment, materials, drugs, medical        | None  |
|   | writing, gifts or other services                       |       |
| 13| Other financial or non-financial interests             | None  |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** August 16, 2021

**Your Name:** Michelle Miller

**Manuscript Title:** EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials

**Manuscript number (if known):**

---

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |

---

**Time frame: Since the initial planning of the work**

**Time frame: past 36 months**
|   |                                                                 |   |
|---|-----------------------------------------------------------------|---|
| 4 | Consulting fees                                                | None |
| 5 | Payment or honoraria for lectures, presentations, speakers      | None |
|   | bureaus, manuscript writing or educational events               |     |
| 6 | Payment for expert testimony                                    | None |
| 7 | Support for attending meetings and/or travel                    | None |
| 8 | Patents planned, issued or pending                               | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory      | None |
|   | Board                                                            |     |
| 10| Leadership or fiduciary role in other board, society, committee | None |
|   | or advocacy group, paid or unpaid                                |     |
| 11| Stock or stock options                                          | Yes: |
|   | Hold stocks and shares in GSK                                   |     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts  | None |
|   | or other services                                               |     |
| 13| Other financial or non-financial interests                       | None |

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date:______August 16, 2021
Your Name:____________Saira Sheikh
Manuscript Title:_______EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials_______
Manuscript number (if known):____________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)**No time limit for this item.** | Yes:
The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Pfizer |
| 3 | Royalties or licenses | None |

**Time frame: Since the initial planning of the work**

**Time frame: past 36 months**
|   | Consulting fees                                                                 | Participation in Data Safety Monitoring Board for an NIH-funded clinical trial |
|---|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None                                                                           |
| 6 | Payment for expert testimony                                                    | None                                                                           |
| 7 | Support for attending meetings and/or travel                                    | None                                                                           |
| 8 | Patents planned, issued or pending                                              | None                                                                           |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board               | Advisory Board for GSK, Aurinia Pharmaceuticals Inc, AstraZeneca, & Eli Lilly & Company |
|   |                                                                                | DSMB for NIH Funded Clinical Trial                                            |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None                                                                           |
| 11| Stock or stock options                                                          | None                                                                           |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None                                                                           |
| 13| Other financial or non-financial interests                                      | None                                                                           |

Please place an “X” next to the following statement to indicate your agreement:

_X_. I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date:______August 16, 2021______________________________
Your Name:____________Susan W Burriss_____________________
Manuscript Title:_______EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials ________
Manuscript number (if known):__________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Yes: The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
|   | Time frame: Since the initial planning of the work | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
|   | Time frame: past 36 months | |
| 3 | Royalties or licenses | None |
|   | | |
|   | Consulting fees | None |
|---|----------------|------|
|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
|   | Payment for expert testimony | None |
|   | Support for attending meetings and/or travel | None |
|   | Patents planned, issued or pending | None |
|   | Participation on a Data Safety Monitoring Board or Advisory Board | None |
|   | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
|   | Stock or stock options | Yes: Hold stocks and shares in GSK |
|   | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
|   | Other financial or non-financial interests | Employee of GSK |

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date:______August 16, 2021______
Your Name:____________Tessa R Englund____________________________________________________________
Manuscript Title:_______EMBRACE: One Small Story in Lupus – One Giant Challenge in Clinical Trials_______
Manuscript number (if known):__________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | **All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.** | **Yes:**
The EMBRACE study (GSK Study BEL115471; NCT01632241) was funded by GlaxoSmithKline (GSK). Editorial checks and submission support were provided by Fishawack Indicia Ltd and was funded by GSK. |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |

**Time frame: Since the initial planning of the work**

**Time frame: past 36 months**
|   | Description                                                                 | None |
|---|-----------------------------------------------------------------------------|------|
| 4 | Consulting fees                                                            |      |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |      |
| 6 | Payment for expert testimony                                                |      |
| 7 | Support for attending meetings and/or travel                                |      |
| 8 | Patents planned, issued or pending                                          |      |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           |      |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |      |
| 11| Stock or stock options                                                      |      |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services |      |
| 13| Other financial or non-financial interests                                  |      |

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.